Fierce Pharma

AUGUST 10, 2023

After Pfizer allegedly fired a compliance manager for raising the flag on potential fraud activity in China, the former employee is hitting back. | Frank Han, Pfizer's former director of global compliance analytics, has filed a civil complaint against the drugmaker. Han claims he was terminated for identifying potential issues relating to the Foreign Corrupt Practices Act.

Management 246

Management 246

Clarity Engagement Solutions

AUGUST 10, 2023

August 10, 2023 Episode 1: The Role of ChatGPT in Strategic Account Management Adipiscing elit dapibus, vulpu tate in donec tempor ultricies venenatis erat, aliquam posuere urna habitant rutrum euismod maecenas varius tortor nibh, sit amet tempor nibh finibus et. Episode 201: Leveling Up Your Career with Jane Chapman [link] Nulla porttitor accumsan tincidunt.

Management 91

Management 91

PharmExec

AUGUST 11, 2023

How pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.

Medical 98

Medical Pharma Marketing 98

European Pharmaceutical Review

AUGUST 10, 2023

The US Food and Drug Administration (FDA) has granted accelerated approval of TALVEY (talquetamab-tgvs) to treat multiple myeloma. Janssen Pharmaceutical Companies of Johnson & Johnson’s first-in-class bispecific T-cell engaging antibody showed an overall response rate (ORR) of over 70 percent in heavily pre-treated multiple myeloma. Based on this data, TALVEY is indicated for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, includin

Food and Drug Administration 98

Food and Drug Administration Food Pharmaceutical Patients 98

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

AUGUST 9, 2023

AstraZeneca is often at the forefront when it comes to sustainability efforts among pharma companies. Now, the British drugmaker is doubling down on its clean energy commitments in Sweden.

Pharma 246

Pharma 246

Eversana Intouch

AUGUST 10, 2023

The industry challenges faced in marketing in the rare disease space are not new. Small populations. Limited understanding of the patient or disease. Diagnostic odysseys that last, on average, seven years and are riddled with misdiagnosis. What is new, however, is the opportunity. At EVERSANA INTOUCH, our rare expertise and advanced technologies are helping solve some of the most difficult challenges in rare disease marketing.

Patients 98

Patients Competition Marketing Healthcare 98

PM360

AUGUST 9, 2023

Real Chemistry , a leading provider of AI-driven insights and marketing and communications for the healthcare industry, is partnering with WhizAI , a generative AI-powered analytics platform purpose-built for life sciences and healthcare, to develop a patient journey visualization and analytics solution. This new platform promises to make it easier for clients to access accurate, contextual insights by asking conversational questions while also having the ability to visualize the process patient

Patients 98

Patients Healthcare Healthcare Training 98

Fierce Pharma

AUGUST 11, 2023

It’s been a rough summer for pharmaceutical companies trying to resolve lawsuits by declaring bankruptcy. | The Supreme Court has halted Purdue Pharma’s $6-billion bankruptcy settlement, which granted the company’s former owners—the Sackler family—immunity from civil suits related to the opioid crisis.

Pharma 246

Pharma Pharmaceutical 246

European Pharmaceutical Review

AUGUST 9, 2023

According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments. The data showed that Daiichi Sankyo , Seagen and Roche are currently three of the most important companies in the ADC market. Daiichi Sankyo was predicted to remain the dominant player in this market.

Marketing 98

Marketing Pharmaceutical Manufacturing 98

PharmExec

AUGUST 10, 2023

Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.

Media 98

Media Education Medical 98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Commerce

AUGUST 7, 2023

Creating a user-centric approach that harnesses both digital tools and behavioral science is key to getting—and maintaining—patients on therapy, and improving clinical, financial, and, ultimately, brand-success outcomes for pharma manufacturers.

Manufacturing 98

Manufacturing Pharma Patients 98

Fierce Pharma

AUGUST 7, 2023

Less than four months after Astellas’ $5.9 billion buyout of eye disease specialist Iveric Bio, the deal is already making the Tokyo-based company look visionary. | Less than four months after Astellas’ $5.9 billion buyout of Iveric Bio, the FDA has signed off on the main asset acquired in the deal, the geographic atrophy treatment Izervay.

FDA 245

FDA Marketing 245

European Pharmaceutical Review

AUGUST 11, 2023

The European Commission has revoked the conditional marketing authorisation (MA) for Novartis’ sickle cell medicine crizanlizumab in the European Union (EU) and EEA. The decision follows a May recommendation from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP). Crizanlizumab is a once-a-month, humanised monoclonal antibody infusion, indicated for the prevention of recurrent vaso‑occlusive crises (pain crises) in sickle cell disease patients aged 16 yea

Marketing 98

Marketing Food and Drug Administration Medicine FDA 98

PharmExec

AUGUST 8, 2023

The precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.

Healthcare 98

Healthcare Healthcare 98

Advertisement

PharmaTech

AUGUST 8, 2023

Catalent's Martin De Brauwere and Maria Lopez react to cell therapy innovations and highlight strategies to optimize the drug development and manufacturing process with assistance from a CDMO.

Manufacturing 98

Manufacturing 98

Fierce Pharma

AUGUST 8, 2023

Novo Nordisk has been riding the momentum of weight loss drug Wegovy ever since it stormed onto the market in 2021, creating widespread hype and even some supply shortfalls. | In a large phase 3 trial, Wegovy cut the risk of major adverse cardiovascular events by 20% compared with placebo and standard of care, Novo said Tuesday. Specifically, investigators measured Wegovy's 2.4-mg dose for its ability to cut the risk of a cardio death, heart attack or stroke.

Marketing 244

Marketing 244

European Pharmaceutical Review

AUGUST 8, 2023

Headline results from Novo Nordisk’s “landmark” SELECT trial in cardiovascular outcomes has demonstrated a 20 percent reduction in major adverse cardiovascular events (MACEs) for semaglutide 2.4mg (Wegovy ® ) compared to a placebo. “People living with obesity have an increased risk of cardiovascular disease but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardio

Management 98

Management Patients Medical Pharmaceutical 98

PharmExec

AUGUST 10, 2023

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

Pharma 98

Pharma 98

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Pharmaceutical Technology

AUGUST 9, 2023

The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.

Pharmaceutical 98

Pharmaceutical 98

Fierce Pharma

AUGUST 8, 2023

It took Bayer’s new CEO Bill Anderson about 20 seconds into his first quarterly conference call to go against the grain. | In his first quarterly earnings call since taking over as CEO at Bayer, Bill Anderson faced several questions about the structure of the company. He said to stay tuned until early 2024. The company reported a 14% decline in revenue for the quarter, with all three business sectors seeing a drop in sales.

Sales 244

Sales 244

European Pharmaceutical Review

AUGUST 7, 2023

Astellas Pharma has agreed to invest a total of $50 million for the right to license P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumour indications. Under the agreement, the company will acquire approximately 8.8 percent of Poseida Therapeutics. Astellas Pharma will receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1.

Pharma 98

Pharma Safety Leads Pharmaceutical 98

PharmExec

AUGUST 7, 2023

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways companies can remain accountable for DE&I efforts in pharma in this Pharmaceutical Executive Podcast video.

Pharma 98

Pharma Pharmaceutical 98

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaVoice

AUGUST 8, 2023

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

Medicine 97

Medicine 97

Fierce Pharma

AUGUST 11, 2023

Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug Relyvrio continues to wow Wall Street. | Amylyx’s amyotrophic lateral sclerosis drug Relyvrio ​​​​​​​continues to wow Wall Street. The drug brought in $98.2 million revenue in the second quarter, handily beating analysts’ consensus estimates of below $92 million.

Pharmaceutical 244

Pharmaceutical 244

European Pharmaceutical Review

AUGUST 8, 2023

Two of AstraZeneca’s key medicines have been recommended for use within NHS Scotland by the Scottish Medicines Consortium (SMC). Tom Keith-Roach, President of AstraZeneca UK announced: “We are pleased that the SMC has now accepted Forxiga (dapagliflozin) for use in patients with chronic heart failure with preserved or mildly reduced ejection fraction and Tezspire (tezepelumab) has been accepted for restricted use in severe asthma within NHS Scotland.

Medicine 98

Medicine Patients Pharmaceutical 98

Pharmaceutical Technology

AUGUST 9, 2023

The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.

Pharmaceutical 96

Pharmaceutical 96

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

MedCity News

AUGUST 9, 2023

Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.

Healthcare 98

Healthcare Healthcare Physicians Patients 98

Fierce Pharma

AUGUST 11, 2023

Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical syste | Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical system.

Medical 243

Medical 243

European Pharmaceutical Review

AUGUST 10, 2023

Novo Nordisk A/S has agreed to acquire Inversago Pharma for up to $1.075 billion. Inversago Pharma is developing CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. What Novo Nordisk will gain from the acquisition Through the acquisition agreement, the pharma company Novo Nordisk intends to investigate Inversago Pharma’s lead development asset, a potential first-in-class small molecule CB1 receptor (CB1r) blocker CB

Pharma 97

Pharma Leads Safety Medicine 97

Impetus Digital

AUGUST 10, 2023

The Problem With in-person meetings resuming after the end of COVID-19-related restrictions, many of our clients have been eager to get back to these meetings, thinking that’s what their Key Opinion Leaders (KOLs) want. Traditionally, external pharmaceutical meetings such as national advisory boards are held at upscale hotels in large cities, no more than once or twice a year.

Pharmaceutical 96

Pharmaceutical Transportation Food Biopharma 96

Advertisement

Distribution